Frontlight ResearchEarly access
CompletedPhase 3
A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder.
Key facts
- Who runs it
- Luye Pharma Group Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 555 people enrolled
- Started
- 4 Aug 2023
- Ended
- 31 Jul 2025
- Type of study
- Interventional, 3 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- Toludesvenlafaxine Hydrochloride Sustained-release Tablet 80mg
- Toludesvenlafaxine Hydrochloride Sustained-release Tablet 160mg
- placebo
- Record updated
- 8 July 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Male or female aged 18 to 65 years subjects
- Meet the Diagnostic and Statistical Manual of Manual Disorders, fifth Edition(DSM-5) criteria for Generalized Anxiety Disorder
- Have a Hamilton Anxiety(HAMA) Rating Scale total score ≥21 points at screening and baseline
- Have a Hamilton Anxiety(HAMA) Rating Scale score ≥2 points on both item 1(anxious mood) and item 2(tension) at screening and baseline
- Have a clinical Global Impression -severity illness (CGI-S) score≥4 points at screening and baseline
Who cannot take part
- Meet the diagnostic criteria for other psychotic disorders(defined by DSM-5, except for GAD), including major depression disorder within 6 months prior to screening , presence or history of Schizophrenia Spectrum and Other Psychotic Disorders, Bipolar and Related Disorders, Obsessive-Compulsive and related Disorders, post-traumatic stress disorder, anorexia nervosa or bulimia and personality disorder
- Meet the diagnostic criteria for substance or alcohol abuse (defined by DSM-5, except for nicotine or caffeine) within 6 months prior to screening
- Withdrawal psychotropic drugs within 5 half-lives (at least 2 weeks for monoamine oxidase inhibitors, at least 1 month for fluoxetine, and at least 2 weeks for benzodiazepines or barbiturates) prior to randomization
- Have received psychosurgery or physical therapy for psychiatric illness (such as transcranial magnetic stimulation) within 3 months prior to screening
- Have received systematic psychotherapy or other non-drug therapies for psychiatric disorders (such as acupuncture or light therapy) within 6 weeks prior to screening
- Concomitant with serious and unstable illness, including cardiovascular, hepatic, renal, hematological, endocrine illness, malignant tumors and other physical illness
- Have anxious symtoms secondary to other physical illnesses or mental illnesses and anxious induced by psychoactive substance
- Have a history of seizures (except for seizures caused by febrile convulsions in childhood)
- Have a history of gastrointestinal disease or surgery known to interfere with investigation product absorption or excretion
- Known or suspected allergic or severe reaction to investigation product or inactive ingredients; or allergic to venlafaxine or desvenlafaxine; or allergic constitution (defined as allergic to two or more drugs or food) and unfit to participate judged by investigator
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The study aims to evaluate the efficacy and safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets compared to placebo in adults participants with generalized anxiety disorder over a period of 8 weeks.
The 3 groups in the trial
- Toludesvenlafaxine Hydrochloride Sustained-release Tablets 80 mg groupTreatment being tested
orally once a day
Treatment: Toludesvenlafaxine Hydrochloride Sustained-release Tablet 80mg
- Toludesvenlafaxine Hydrochloride Sustained-release Tablets 160 mg groupTreatment being tested
orally once a day
Treatment: Toludesvenlafaxine Hydrochloride Sustained-release Tablet 160mg
- PlaceboSham treatment, for comparison
orally once a day
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Participants With Generalized Anxiety Disorder.
- Record updated
- 8 July 2026